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Hereditary Breast and Ovarian Cancer (HBOC) syndrome is due to mutations in 
BRCA1 and BRCA2 genes.  Women with HBOC have high risks to develop breast and 
ovarian cancers. Males with HBOC are commonly overlooked because male breast cancer is 
rare and other male cancer risks such as prostate and pancreatic cancers are relatively low. 
BRCA genetic testing is indicated for men as it is currently estimated that 4-40% of male 
breast cancers result from a BRCA1 or BRCA2 mutation (Ottini, 2010) and management 
recommendations can be made based on genetic test results.  Risk assessment models are 
available to provide the individualized likelihood to have a BRCA mutation.  Only one study 
has been conducted to date to evaluate the accuracy of BRCAPro in males and was based on 
a cohort of Italian males and utilized an older version of BRCAPro. 
The objective of this study is to determine if BRCAPro5.1 is a valid risk assessment 
model for males who present to MD Anderson Cancer Center for BRCA genetic testing. 
BRCAPro has been previously validated for determining the probability of carrying a BRCA 
mutation, however has not been further examined particularly in males.   
The total cohort consisted of 152 males who had undergone BRCA genetic testing. 
The cohort was stratified by indication for genetic counseling. Indications included having a 
known familial BRCA mutation, having a personal diagnosis of a BRCA-related cancer, or 
having a family history suggestive of HBOC.  Overall there were 22 (14.47%) BRCA1+ 
males and 25 (16.45%) BRCA2+ males. Receiver operating characteristic curves were 
constructed for the cohort overall, for each particular indication, as well as for each cancer 
subtype. Our findings revealed that the BRCAPro5.1 model had perfect discriminating 
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ability at a threshold of 56.2 for males with breast cancer, however only 2 (4.35%) of 46 
were found to have BRCA2 mutations.   
These results are significantly lower than the high approximation (40%) reported in 
previous literature.  BRCAPro does perform well in certain situations for men.  Future 
investigation of male breast cancer and men at risk for BRCA mutations is necessary to 
provide a more accurate risk assessment. 
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BACKGROUND 
 
Introduction 
Hereditary Breast and Ovarian Cancer (HBOC) is a hereditary cancer syndrome 
caused by mutations in the BRCA1 and BRCA2 genes and is inherited in an autosomal 
dominant manner.  Since the discovery of BRCA1 and BRCA2 genes in 1994 and 1995, 
respectively [1,2]  there have been many research studies conducted on this topic.  The 
BRCA1 gene is located on chromosome 17q21, consists of 1,863 amino acids, and plays an 
important role in DNA repair, cell-cycle-checkpoint control, protein ubiquitylation and 
chromatin remodeling [3]. The BRCA2 gene is located on chromosome 13q12.3 and consists 
of 3,418 amino acids. To date, the exact function of BRCA2 is not as well known, however 
both BRCA1 and BRCA2 play important roles in DNA repair, more specifically in 
homologous recombination [3]. Inheriting a BRCA1 or a BRCA2 mutation puts both males 
and females at risk to develop certain types of cancers at earlier ages than the general 
population.  
Mutations in BRCA1 and BRCA2 confer the highest risk for women to develop breast 
and ovarian cancers. Women who are found to be BRCA1 mutation carriers have up to an 
85% lifetime risk of developing breast cancer and a 45% lifetime risk of developing ovarian 
cancer [4].  For women who are BRCA2 mutation carriers, the lifetime risks to develop 
breast and ovarian cancer are up to an 84% risk and an up to a 27% risk, respectively [5]. 
These numbers are increased well above the general population lifetime risks for a woman 
to develop breast cancer and ovarian cancer. According to Surveillance, Epidemiology and 
End Results (SEER) the general lifetime population risk for women to develop breast cancer 
is 12.29% [6]. SEER data estimates that the general population lifetime risk for women to 
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develop ovarian cancer is 1.40% [6]. The vast majority of information known about BRCA1 
and BRCA2 is through research conducted on women with BRCA mutations. 
BRCA1 and BRCA2 mutations are aolso associated with an increased risk for men to 
develop male breast cancer and prostate cancer with a higher risk conferred by having a 
BRCA2 mutation [7]. The general population lifetime risk for men to develop prostate 
cancer is 16% [8]. The general population lifetime risk for men to develop breast cancer is 
0.1% [9]. Both male and female BRCA2 mutation carriers are at an increased risk to develop 
pancreatic cancers with up to a 7% lifetime risk seen for males and up to a 3% lifetime risk 
seen for females [5]. 
 
Male Breast Cancer  
Male breast cancer is extremely rare and only accounts for 1% of all breast cancers 
[10].  In the United States, it is estimated that there are approximately 1,970 new cases of 
male breast cancer diagnosed each year with 390 deaths resulting from male breast cancer 
[10].  Male breast cancer usually first comes to attention due to one or more of the following 
symptoms: painless subareolar lump, nipple retraction, or bleeding from the nipple [11].  In 
comparison female breast cancers are commonly diagnosed through one of two methods, 
which include screening measures such as breast mammograms, MRIs, and ultrasounds or 
when the tumor has grown to a size that creates a lump that is palpable on physical exam 
[12].  Less common signs and symptoms in female breast cancers include breast pain or 
heaviness, swelling, thickening or redness of the skin covering the breast, nipple discharge, 
and changes to the nipple such as erosion, inversion, or tenderness [12]. Screening 
mammography starting at age 40 for women in the general population is universally 
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recommended [13].  The advances made in screening technology along with addition in 
adjuvant advances can be attributed to the 2.2% per year decrease seen in breast cancer 
mortality rates in the United States since 1990 [5].  
Male breast cancers historically differ from female breast cancers in several different 
aspects.  Male breast cancers, when compared to female breast cancers, are diagnosed at 
later ages and at more advanced clinical stages, with greater tumor sizes and more frequent 
involvement of the lymph nodes [9].  In comparison to the mean age of diagnosis of breast 
cancer in women of 62 years, male breast cancer is diagnosed five years later, with the mean 
age of diagnosis for male breast cancer being 67 years [11]. A similarity seen between male 
and female breast cancer is that there is a slight preponderance of left-sided disease over 
right-sided disease [11].  
Tumor marker status for male breast cancers differs when compared to female breast 
cancers, as these markers are much more likely to be both estrogen and progesterone 
receptor positive. More than 90% of male breast cancers are found to be estrogen receptor 
positive, with the majority also being progesterone receptor positive at approximately 81% 
[11,14].  Male breast cancers are most commonly found to be HER2 negative, with 
estimation that only 10% of male breast cancer tumors demonstrate HER2 amplification 
[15].   
The Surveillance, Epidemiology, and End Results (SEER) registry collected data on 
breast cancer from 1973 through 2005 and has a collection of 5,494 male breast cancer cases 
[9]. The SEER data set found that in their male breast cancer cases, 11% were diagnosed 
with ductal carcinoma in situ [9].  Most frequently, male breast cancer is confirmed by 
pathology to be invasive ductal carcinoma [11].  In male breast cancer, the histology 
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subtypes of lobular, mucinous, medullary and papillary account for only about 5% of cases 
[11].  The risk to develop breast cancer increases at a steady linear rate in regard to age for 
males with a peak being reached at approximately 75 years of age [9]. The linear rate 
observed in male breast cancers is in contrast to the bimodal distribution, also known as 
Clemmesen’s hook, seen in regard to age of diagnosis for females [9].  The incidence of 
male breast cancer varies based on race, for example black males having a higher incidence 
of 1.8 per 100,000 as compared to white males having an incidence of 1.1 per 100,000 [9]. 
 
Male Breast Cancer Risk Factors  
 There are many different factors that may increase a male’s risk to develop breast 
cancer in his lifetime.  In addition to mutations in BRCA1 and BRCA2, there are other 
genetic factors that have been suggested as conferring an increased risk for male breast 
cancer, more specifically mutations in PTEN, CHEK2 [9].  The risks for male breast cancer 
associated with mutations in PTEN, CHEK2 are substantially lower than the risk for male 
breast cancer with a BRCA1 or BRCA2 mutation.  Klinfelter syndrome, a sex chromosome 
disorder diagnosed with karyotype of XXY, has been described as occurring in 3% to 7.5% 
of males with breast cancer [9,11].  Individuals with Klinefelter syndrome have been 
suggested to have up to a 50 times higher risk to develop breast cancer in comparison to 
males in the general population [16].  Determining the exact risk factor for male breast 
cancer in regard to Klinefelter syndrome is complicated due to the relative rarity of these 
two factors.  
Gynecomastia is defined as the abnormal development of large mammary glands 
resulting in breast enlargement in males [16].  It is thought that gynecomastia is a risk factor 
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for the development of male breast cancer due to an increased amount of breast tissue.  
Gynecomastia is the most common benign breast condition noted in males, occurring in 
approximately 30% of healthy men [11,17].  Having at least one female relative diagnosed 
with breast cancer increases a man’s likelihood to develop breast cancer 2.5 times [11].  In 
summary, risk factors for the development of male breast cancer include genetic mutations, 
hormonal and personal factors, family history of breast cancer, and environmental factors.  
Both males and females who receive chest wall radiation for various indications such as 
treatment for Hodgkin’s lymphoma are at increased risk to develop breast cancer [11].  
Several risk factors have been proposed to exist with male breast cancer and include alcohol 
use, liver disease, obesity, electromagnetic field radiation and diet; although further 
investigation is needed at this point to prove associations [11].  
 
Treatment for Male Breast Cancer  
 As previously stated, male breast cancer is rare; due to this fact there have only been 
retrospective analyses performed in evaluating treatment options for male breast cancer at 
this point in time.  Treatment choices for male breast cancer are similar to the options 
available for female breast cancer and include surgery, adjuvant therapy, radiation and 
chemoprevention [18].  In regard to surgical options, males generally undergo a modified 
radical mastectomy due to the relatively small amount of male breast tissue along with the 
fact that most male breast tumors are centrally located [19].   Male breast cancer patients are 
more likely than their female counterparts to receive radiation due to the presence of 
advanced disease [20]. Since the vast majority of male breast cancers are estrogen and 
progesterone positive tumors, the chemoprevention agent Tamoxifen has recently been 
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studied in this patient population based on data established in female breast cancers that this 
agent improves survival along with decreasing recurrences of breast cancer [18]. There are 
concerns that need to be considered when prescribing hormonal agents like Tamoxifen to 
male patients, such as potential undesirable side effects, which may cause males to 
discontinue this treatment [21].  Pemmaraju et al. (2011) recently carried out a retrospective 
review of 64 male breast cancer patients who were treated with Tamoxifen and found that 
20.3% of patients altogether discontinued Tamoxifen citing specific side effects.  In addition 
to clinicians continuing to increase patient awareness of unpleasant side effects, more 
research is needed focused on evaluating the use of Tamoxifen in males.   
 
Prostate Cancer  
 Prostate cancer is currently the most commonly diagnosed male cancer in North 
America [22].  It is estimated that in 2011, 240,000 men will be diagnosed with prostate 
cancer and result in 34,000 deaths [8]. It has been established that BRCA2 carriers have 
between a 2-5 relative risk for prostate cancer, whereas BRCA1 carriers have between a 1-3 
relative risk [21].  The NCCN guidelines recommend that both the risks and benefits of 
screening for prostate cancer be discussed with male BRCA carriers at age 40.  The 
American Cancer Society recommends that men at high risk for developing prostate cancer 
should begin having specific antigen tests (PSA) and digital rectal examinations (DRE) at 
age 40.  The American Cancer Society defines high risk as males who have multiple 
relatives with prostate cancer, which is an important distinction to make since this definition 
does not specifically include BRCA carriers.  However, the utility of prostate screening is 
currently a subject of contention and disagreement among many medical professionals.  It 
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will be imperative in the coming years for both male BRCA carriers as well as men in the 
general population to stay abreast on research regarding this topic. 
 
Prostate Cancer Risk Factors and Treatment  
  There are numerous risk factors that are known to increase the risk for prostate 
cancer in males.  Increasing age, positive family history, and being of African American 
heritage are the risk factors that are have been found to be most strongly associated with 
prostate cancer [23].  “The median age of diagnosis of prostate cancer is 67 years and the 
median age of death is 81 years” [22].  Men who have at a first degree relative diagnosed 
with prostate cancer are at a two-fold increased risk to develop prostate cancer in 
compassion to their counterparts with no apparent family history [24].  For reasons not well 
understood at this point in time, African American males have a higher incidence of prostate 
cancer and are also more likely to receive the diagnosis at an advanced stage of disease 
when compared to Caucasian and Hispanic males [23].   
 Once a prostate cancer is detected there are numerous different approaches to 
managing the disease, often times decisions are based on several different factors such as the 
patient’s age, if the cancer has spread, other medical conditions, along with the patient’s 
overall health [25]. There are several different treatment options when the prostate cancer 
has not metastasized and include watchful waiting, radical prostatectomy, radiation therapy 
either internal or external, hormone therapy, and crypotherapy [25].  
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 Pancreatic Cancer  
 Of all cancers diagnosed in the United States, pancreatic cancers are the fourth 
deadliest [26].  Although rare in occurrence, representing only 3% of cancers each year, 
pancreatic cancer accounts for 6% of all cancer related deaths [10] (Jemal et al, 2007).  It is 
estimated that 10% of pancreatic cancers are due to heritable genetic mutations and/or 
familial patterning of inheritance [27,28].  BRCA mutation carriers are at increased risk to 
develop pancreatic cancer, with BRCA2 carriers having around a 5% lifetime risk to develop 
pancreatic cancer [5]. It is estimated that BRCA1 mutation carriers have approximately a 
2.26 increased risk to develop pancreatic cancer in comparison to the general population 
[29]. In the Ashkenazi Jewish population, there is a particular BRCA2 mutation, 6174delT, 
that has been found in families who have higher incidences of pancreatic cancer [26].  In the 
Asheknazi Jewish population BRCA2 mutations have been found to be associated with 10% 
of unselected, apparently sporadic pancreatic cancers [30]. Unfortunately at this point in 
time there are not reliable methods for screening and early detection of pancreatic cancers, 
even though individuals at increased risk based on gene mutations or family history could 
benefit from such screening.  Detecting small pancreatic cancers along with premalignant 
lesions of the pancreas is complicated by the fact that neither lesion shows symptoms [26] . 
If an individual is identified as being at an increased risk for the development of pancreatic 
cancer, there are several available ongoing clinical trials looking to identify the most reliable 
screening method for this patient population.  
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Pancreatic Cancer Risk Factors and Treatment 
 Pancreatic cancer is considered to be multifactoral in its development.  Risk factors 
include smoking, family history of chronic pancreatitis, advancing age, male sex, diabetes 
mellitus, obesity, non-O blood type, occupational exposures such as nickel, and diet [31]. 
Possible risk factors for pancreatic cancer may include Helicobacter pylori infection and 
periodontal disease [29].  Another genetic risk factor for developing pancreatic cancer is 
seen in individuals with hereditary pancreatitis, which is a rare inherited form of chronic 
pancreatitis caused by germline PRSS1 mutations [32]. Notably a positive history of 
cigarette smoking and/or use of other tobacco products is present in 20% of all patients with 
pancreatic tumors [33].   
For pancreatic cancer patients, the only potentially curative treatment is a 
pancreatectomy, for which only 15-20% of patients will qualify for this course of treatment 
[32].  In comparison to patients with unresectable pancreatic tumors, patients who undergo a 
pancreatectomy have a higher 5-year survival rate, although it is still relatively low with the 
5 year survival rate being 25-30% in node-negative patients and 10% in node-positive 
patients [30].   
 
BRCA Testing in males who present with BRCA associated cancers  
BRCA genetic testing is indicated in this patient population as it is currently 
estimated that up to 40% of male breast cancers result from a BRCA2 mutation whereas up 
to 4% of cases are estimated to result from a BRCA1 mutation [7,14,34].  Males who are 
known BRCA1 mutation carriers are quoted as having a 5.8% lifetime risk to develop breast 
cancer, whereas males with a known BRCA2 mutation have a 6.9% lifetime risk to develop 
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breast cancer, which is 80-100 times increased above the general population risk [7].  The 
general population lifetime risk to develop breast cancer for males is 0.1% [9]. Mutations in 
both BRCA genes also confer an increased risk for males to develop prostate and pancreatic 
cancers [7]. In regard to BRCA mutations it is more common for males with breast cancer to 
be BRCA2 mutation carriers. Although one study found that more than one-third of the 
BRCA mutations that were identified in their cohort of 76 men with breast cancer were 
BRCA1 [35]. A predisposition to develop other cancers such as melanoma and stomach 
cancer may also exist due to BRCA1 and BRCA2 mutations [22].  
  
Screening Recommendations  
 The National Comprehensive Cancer Network has put forth screening guidelines 
for men who are found to be BRCA1 or BRCA2 mutation carriers.  The NCCN is 
comprised of 21 cancer centers and is considered to be a leading authority providing expert 
opinions in the field of cancer.  The NCCN 2011guidelines for male BRCA1 and BRCA2 
mutation carriers include:  
“breast self-exam training and education starting at age 35, clinical breast exam , 
every 6-12 months, starting at age 35 years, consider baseline mammogram at age 
40; annual mammogram if gynecomastia or parenchymal/glandular breast density on 
baseline study, as well as adhere to screening guidelines for prostate cancer.” [36]  
In males undergoing mammography, the sensitivity is reported to be 92% with 90% 
specificity in the diagnosis of male breast cancers [11,37].  Because of their increased 
lifetime cancer risks, it is important to identify males with BRCA1 and BRCA2 mutations 
early so that screening can be implemented in the hopes of preventing cancer altogether.  
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Clinical BRCA Testing 
Myriad Genetic Laboratories first made testing for BRCA1 and BRCA2 mutations 
available in 1996 [38]. Currently, genetic counselors and other health care providers utilize 
statistical models along with clinical judgment to determine if individuals are candidates for 
BRCA genetic testing.  Indications for BRCA genetic testing include a personal history of 
early onset breast and/or ovarian cancer and positive family history the family history 
features that are suggestive of a hereditary form of breast and ovarian cancer include: close 
relatives with breast, ovarian or other related cancers, premenopausal breast cancer 
diagnoses, multiple related cancers in an individual, male breast cancer, similar cancers in 
multiple generations, and Ashkenazi Jewish ancestry. The NCCN recommends offering 
BRCA testing to any male diagnosed with breast cancer in order to investigate the possibility 
of a genetic cause; therefore it is routine practice in the clinical setting [36] [39]. 
When considering BRCA genetic testing, it is important to understand the different 
types of tests that are currently available.  If an individual reports being of Ashkenazi Jewish 
ancestry, it is most appropriate to begin testing with the Ashkenazi Jewish Multisite 3 
BRACAnalysis® test.  This is due to the fact that the majority of mutations in Ashkenazi 
Jewish individuals occur in one of three common founder mutations two in BRCA1 
(187delAG, 5385insC) and one in BRCA2 (6174delT) [35]. If there is a known BRCA 
mutation within a family, testing should first be ordered for that particular known familial 
mutation, however if this individual is found to have an Ashkenazi Jewish founder mutation 
then the multi-site panel should be ordered for their family members.  In both of these cases, 
if a negative test result is obtained, there is always the option to additional BRCA testing.  
Therefore, one patient could have multiple types of BRCA testing ordered.  Comprehensive 
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BRCA genetic testing should be the first line of testing ordered for individuals without a 
known familial mutation or any report of Ashkenazi Jewish ancestry.  Comprehensive 
testing involves sequencing both BRCA1 and BRCA2. BRACAnalysis Large Rearrangement 
Test (BART) is testing offered through Myriad clinically as of August 2006 and involves 
testing for large rearrangements, deletions or duplications that are otherwise missed by 
sequencing. The yield for mutations found by BART is relatively low, although varies based 
on ethnic groups.  
After BRCA testing is ordered there are three possible test results that a patient can 
receive.  The first test result is that of a positive result, meaning a mutation was detected.  
Individuals with a positive test result should follow screening recommendations such as 
those outlined by the NCCN and encourage other family members to seek genetic 
counseling and be tested for the mutation that was identified.  A negative test result means 
that no mutation was identified based on the testing ordered.  Individuals who receive this 
result should be considered for additional reflex testing if either their personal and/or family 
history is highly suggestive of HBOC. Lastly, there is the result of a variant of uncertain 
significance meaning that a sequence change was identified, however it is unclear whether 
that specific change is deleterious or a polymorphism.  
 
Risk Assessment Models for Genetic Mutations  
Certain cancer genetic risk assessment models are used by clinicians to give their 
patients an individualized risk to develop a particular cancer or the chance to have a BRCA 
mutation, which in turn can assist patients in making informed decisions about undergoing 
genetic testing.  Three men from Duke University Institute for Statistics and Decision 
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Sciences created BRCAPro [40].  BRCAPro has been validated as an accurate counseling 
tool for determining the probability of carrying BRCA1 and BRCA2 mutations [41].  
BRCAPro utilizes personal history and family history of first and second-degree relatives’ 
diagnoses of cancer in addition to other characteristics such as hormone receptor status 
(breast cancer), oophorectomy, ethnicity, and Ashkenazi Jewish ancestry to provide an 
accurate risk assessment. BRCAPro is a risk assessment model based on Baye’s theorem, 
which takes into account both affected and unaffected individuals to calculate an 
individual’s conditional probability to have a mutation in either BRCA1 or BRCA2.  In the 
case of BRCAPro, the condition is having a personal history of cancer, family history of 
cancer, or both. The question generated by BRCAPro is “given this pattern of affected and 
unaffected relatives, what is the probability that this individual carries a mutation in one of 
the BRCA genes?” [40].  CancerGene Version 5.1 is available as a free online download, 
and includes BRCAPro (UT Southwestern Medical Center of Dallas © 1998-2010).  
BRCAPro version 5.1 has been updated to include race-specific calculations and uses 
Myriad BRCA prevalence tables from February 2010.   
The overall accuracy of this model is dependent on both the frequency and 
penetrance of BRCA mutations in the specific population of interest [42]. An initial 
limitation of BRCAPro as a risk assessment model is that it was developed and thus first 
validated in individuals, mainly women, of Ashkenazi Jewish or European descent and 
therefore may not be as meaningful or useful in minority populations [42]. Minority 
populations represent less than 10% of individuals who uptake BRCA genetic testing, 
according to data from Myriad Genetic Laboratories [42]. The small number of minorities 
who have undergone BRCA genetic testing only further complicates the issue of validating 
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BRCAPro in these populations.  However, one study conducted in 2009 studied a total of 
292 minority families which included African Americans, Hispanics, Asian-Americans, 
Native Americans as well as a few other less represented minorities in the United States, 
who had at least one family member who had undergone BRCA mutational testing in order 
to access BRCAPro’s ability to accurately detect mutation carriers. This study found that 
BRCAPro performed the most reliably in Hispanics with the highest AUC of 0.83, and the 
least reliably in African Americans with an AUC of 0.68 [42]. Similar to the small number 
of studies that have focused on validating BRCAPro use in minority populations, relatively 
no studies have focused on the utilization of this model in males.  
Zanna et al, (2010) found in their study of 102 Italian men with breast cancer, that 
BRCAPro had the highest combination of sensitivity, specificity, negative predictive value, 
and positive predictive value out of four different risk assessment models [34].  However, 
further research is needed for the male breast cancer population and males in general 
undergoing BRCA genetic testing. 
One recent study found the BRCAPro model was overestimating the relative 
contribution that female bilateral breast cancer had on the likelihood of detecting either a 
BRCA1 or BRCA2 mutation in their cohort of 66 women with a personal history of bilateral 
breast cancer [43].  Further investigation into male breast cancer may produce findings 
similar to Ready et al, (2009) in regard to BRCAPro overestimating their likelihood to be 
BRCA mutation carriers. 
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Objective 
The objective of this study was to determine if BRCAPro is a valid risk assessment 
model to use for all males who present for BRCA genetic testing. Findings from this study 
will help clinicians offering testing to male breast cancer patients or who have a significant 
family history that is suggestive of HBOC to determine the most appropriate testing 
candidates and accurately assess their risk to test positive. Additionally, this study may 
facilitate the development of a new risk assessment model specifically for males, if the 
BRCAPro model is not validated in this study population.  
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METHODS AND MATERIALS 
This study was a retrospective chart review of all males who have presented to MD 
Anderson Cancer Center for genetic counseling in the high-risk genetics clinics and had 
BRCA testing performed.  A chart review through MD Anderson Cancer Center’s electonric 
medical record (EMR) was performed to obtain relevant information for study participants. 
The specific aim of this study was to determine if BRCAPro version 5.1 is a valid risk 
assessment tool in affected males who have undergone BRCA genetic testing.  Males who 
had undergone predictive testing, or those with a known familial mutation (KFM) were 
included in this study, however were analyzed separately from males affected with a BRCA 
related cancer that presented as the index case in their family for BRCA testing. We 
hypothesized that BRCAPro5.1 will overestimate the likelihood for a male to have either a 
BRCA1 or BRCA2 mutation. 
 
Study Approval  
 The University of Texas-Houston Health Science Center’s Intuitional Review Board 
approved this study on July 25th, 2011. The Committee for the Protection of Human Subjects 
of MD Anderson approved this study on November 3rd, 2011.  
 
Study Population  
 The study population consisted of 152 MD Anderson Cancer Center male patients 
who underwent BRCA testing through Myriad Genetics Laboratory in Salt Lake City, Utah. 
However, one study participant had BRCA testing performed through Oxford Radcliffe 
Hospitals Genetics Laboratories in Oxford, OX.  
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Ascertainment  
 An IRB approved research database at MD Anderson Cancer Center was used to 
identify potential study participants. The study population included patients seen at MD 
Anderson between February 1997 to September 2011.  An initial query revealed 215 males 
had presented to MD Anderson for BRCA testing, however 54 of these patients were 
excluded based on the fact that they were missing medical record numbers.  A total of 161 
patients were identified as potential study participants and their fulfillment of the inclusion 
criteria was confirmed during review of their medical records. Of the 161 patients, in total 
nine were excluded because they did not meet the inclusion criteria of the study. The 
following individuals were excluded from our data: women, individuals who did not have 
electronic medical records on file, individuals who did not have a genetic counseling note as 
reliable family history could not be obtained, males with a variant of uncertain significance 
and no deleterious mutation, males who were identified to have another hereditary cancer 
syndrome aside from HBOC and males whose BRCA testing was never performed. Males 
who were noted to have a variant of uncertain significance in either BRCA1 or BRCA2 that 
were classified as suspected deleterious were included due to the fact that these individuals 
are treated from a clinical standpoint as having a mutation. Males who were noted to have a 
variant of uncertain significance in either BRCA1 or BRCA2 classified as a favored 
polymorphism were included and treated as a negative result. Males who were diagnosed 
with ductal carcinoma in situ (DCIS) were included in the cohort and entered into BRCAPro 
has having DCIS at their age of diagnosis as opposed to entering their DCIS as invasive 
breast cancer developing 10 years after the DCIS.  
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Figure 1: Flowchart of final study population  
 
 
 
 
 
 
 
 
 
 
BRCAPro Risk Calculation  
 All study participants had their individual BRCAPro numbers calculated by entering 
both their personal and family history into the BRCAPro 5.1 model, which generates both a 
pedigree and risk calculation.  Study participants’ ethnicities were recorded by self-report at 
their genetic counseling appointment. Males who were diagnosed with ductal carcinoma in 
situ (DCIS) were included in the cohort and entered into BRCAPro has having DCIS at their 
age of diagnosis as opposed to entering their DCIS as invasive breast cancer developing 10 
years after the DCIS.  Males who were undergoing predictive testing had their KFM entered 
into the program to most accurately predict their own likelihood to test positive.  
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Data Collection  
 The study population’s medical records at MD Anderson Cancer Center were 
reviewed December 2011 through March 2012. The information extracted from the medical 
records is displayed in table 1.  
 
Table 1 Information Obtained from Chart Review through MD Anderson EMR  
 
Demographic and General Information 
Indication for genetic counseling  
Date of birth  
Ethnicity including Ashkenazi Jewish  
Age of diagnosis of all cancer diagnoses  
Height and weight (at initial appointment) to calculate BMI  
Gynecomastia if noted on psychical exam (at initial appointment)  
 
Tumor Information  
Receptor status of breast tumor  
Pathology of tumor  
History of previous biopsy  
Treatment options  
 
Family History  
First and second degree relatives (sometimes third degree) with reported cancer 
diagnoses  
Gender of family members  
Ages of diagnoses of these cancers if reported 
Ages of deaths of these individuals if reported  
Pedigrees constructed from the genetic counseling appointment  
Testing Information  
Type of testing ordered  
Date of testing  
Testing result 
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Statistical Analysis  
 Numerous computer programs were utilized to analyze this data set. Access 2010 
was used to create a secure password protected database for all information collected from 
the chart review portion. Microsoft Excel 2010 was used as a means of organizing the data. 
STATA 10.0 was used to perform descriptive statistics.  
 We constructed receiver operating characteristic (ROC) curves to evaluate the 
discriminatory value of the BRCAPro5.1 model.  ROC curves are constructed by plotting 
the sensitivity on the y axis against 1-specificity on the x axis.  When discussing the 
likelihood of having a BRCA mutation, sensitivity and specificity have equal importance 
since it can be argued harm could be afflicted for calling either false positives or false 
negatives. Therefore, in order to set our threshold value for our ROC curve, the Youden’s 
index (J) was calculated, since it was determined that both sensitivity and specificity are 
equally critical.  The maximum theoretical value for J is 1, in the case of a test having 
perfect discriminatory value or the ability to accurately determine individuals who will test 
positive from those who will test negative.  
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RESULTS  
 In total 152 male patients were included in our cohort; 57% (87/152) presented for 
BRCA testing due to a personal history that was suggestive of a BRCA mutation as defined 
as having a personal diagnosis of male breast cancer, pancreatic cancer and/or prostate 
cancer, 36% of our patients were seen for predictive testing with a KFM and 7% presented 
to clinic due to a family history that was suggestive of a BRCA mutation (Figure 1).  Table 1 
summarizes the number of study participants seen for each indication with 54 males 
presenting to clinic with a KFM, 87 males presenting to clinic due to a personal history 
suggestive of a BRCA mutation (diagnosis of male breast cancer, prostate, pancreas) and 11 
males presenting to clinic due to a family history suggestive of a BRCA mutation. A family 
history suggestive of a BRCA mutation included males of Ashkenazi Jewish ancestry, first 
and/or second degree relatives with early age of onset and higher than expected diagnoses of 
BRCA related cancers in family members (breast, ovarian, prostate, pancreatic).  Therefore, 
the majority of our study cohort was seen due to a personal cancer history that was 
suggestive of a BRCA mutation.  Results from our study were stratified based on the 
indication for having BRCA testing, as these groups were analyzed separately from one 
another. 
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Figure 2: Indication for BRCA Testing  
36%
57%
7%
Indication 
Known Familial Mutation
Personal History Suggestive of a BRCA
Mutation
Family History Suggestive of a BRCA
Mutation
N=152
 
 
Demographics  
The vast majority of our study population was Caucasian with a total of 94 males 
(61.84%). This number increases to 129 males (84.87% ) if you add in the ethnic group who 
reported themselves as Ashkenazi Jewish which is a subset of Caucasian. The ethnicity of 
our cohort is summarized in Table 2.  
The overall mean age of the study cohort at the time they presented for BRCA testing 
was found to be 57.43 with a standard deviation of 14.59 and a range from 19 to 88 years. 
When looking at the dataset stratified by indication, it was noted that the lowest mean age 
was 51.06 with a standard deviation of 17.81 and a range from 19 to 79 years for individuals 
who were undergoing predictive testing.  The highest mean age of 61.31 with a standard was 
seen for individuals who had a personal cancer diagnosis suggestive of a BRCA mutation. 
The findings for the age of our study population are summarized in Table 2.  
When looking at the vital status of our study cohort, it was seen that overall the 
majority of participants were still living (80.26%; n=122) when our chart review was 
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performed, while 30 males were deceased representing 19.74% of the cohort.  The majority 
of deceased males had a personal history of cancer, (93.3%, n=28). The vital status of the 
study participants from the time of the chart review are summarized in Table 2.  
 
Table 2: Demographic Information of Study Cohort  
Variable  Known 
Familial 
Mutation  
Personal 
History  
Family  
History  
Overall  
N  54 (35.53%)  87 (57.24%)  11 (7.24%)  152 
Age (Mean, SD) 51.06 
(17.81) 
61.31 
 (11.36) 
58.36 
(8.26) 
57.43 
(14.59) 
Caucasian  38 (70.37%) 52 (59.77%) 4 (36.36%) 94 (61.84%) 
Ashkenazi 8 (14.82%) 20 (22.99%) 7 (63.64%)  35 (23.03%) 
Hispanic  8 (14.82%) 6 (6.90%)  0   14 (9.21%) 
Black  0  4 (4.60%) 0   4 (2.63%) 
Asian  0  4 (4.60%) 0   4 (2.63%) 
Ethnicity  
Other  0  1 (1.15%) 0   1 (0.66%) 
Alive 51 (41.80%)  63 (51.64%) 8 (6.56%) 122 (80.26%) Vital 
Status  Deceased 2   (6.67%) 28 (93.33%) 0 (0.00%) 30 (19.74%)  
 
Of our total cohort, 46 (30.26%) males were noted to have invasive breast cancer or DCIS.  
The majority of males with breast cancer, 44, had an indication of having a personal diagnosis of 
cancer, whereas the other 2 breast cancers were diagnosed in males who had a KFM.  The overall 
mean age of diagnosis for breast cancer not subdivided by indication was 60.13 with a standard 
deviation of 10.83 and a range from 24 years to 87 years.  The most common pathology was ductal 
accounting for 38 (82.61%) of all the breast cancers diagnosed.  The least common breast pathology 
was mixed lobular and ductal as it was found in only 1 study participant (2.17%). The majority of 
breast cancers diagnosed were both ER+ and PR+ with 40 breast cancers being ER+ and 38 breast 
cancers being PR+, which represented 86.96% and 82.61% respectively of all the breast cancers 
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diagnosed. The findings of breast cancers diagnosed, breast cancer subtype and tumor maker status 
are summarized in Table 3. 
 
Table 3: Breast Cancer Information and Subtype by Indication  
Variable  Known 
Familial 
Mutation 
(n=54)  
Personal 
History 
(n=87)  
Family  
History  
(n=11) 
Overall  
(n=152) 
Breast Cancer Present 2 (3.70%) 
  
44 (50.57%) 
 
0 46 (30.26%) 
Age of Diagnosis 
(Mean, SD)  
62.50 (3.54)  60.02 (11.06) 0  60.13 (10.83) 
Ductal  2 (100%) 36 (81.82%) 0 38 (82.61%) 
DCIS  0 5 (11.36%)  0 5 (10.87%) 
Papillary  0 2 (4.55%) 0 2 (4.35%) 
Breast 
Cancer 
Pathology 
Ductal and 
Lobular  
0 1 (2.27%) 0 1 (2.17%) 
ER+ 2 (100%) 38 (86.36%) 0 40 (86.96%) 
PR+  2 (100%) 36 (81.82%) 0 38 (82.61%) 
Tumor 
Markers 
Her2neu+ 1 (50%) 3 (6.82%) 0 4 (8.70%)  
 
 In addition to breast cancer, males in our study were noted to have several other 
BRCA associated cancers.  Across all three indications, prostate cancer was diagnosed in 21 
males, which represented 13.82% of the entire study population.  Overall the mean age of 
diagnosis of prostate cancer was 57.47 with a standard deviation of 6.33 and a range from 
47-70.  Of the 21 prostate cases diagnosed, 16 cases were diagnosed in males seen due to 
their cancer diagnosis while 5 cases of prostate cancers were diagnosed in males seen due to 
having a KFM.  Across all three indications, pancreatic cancer was diagnosed in 39 patients 
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(25.66%). Pancreatic cancer had a mean age of diagnosis of 56.16 years with a standard 
deviation of 10.64 and a range from 34 to 80 years. Additionally, other cancer diagnoses 
were also collected from the medical records. Overall the mean age of diagnosis of other 
cancers was 58.60 with a standard deviation of 13.26 and a range from 33 to 80 years. Of the 
54 males seen for an indication of a KFM, 10 (18.52%) were noted to have other cancers 
that are not currently known to be associated with BRCA mutations and included: bladder 
cancer, squamous cell carcinoma of the tongue, appendix cancer, colon cancer, basal cell 
carcinoma, and duodenum.  Of the 87 males seen for a personal cancer diagnosis suggestive 
of a BRCA mutation, 21 (24.14%) were noted to have other additional cancer diagnoses 
which included: basal cell carcinoma, pituitary cancer, bladder cancer, duodenal cancer, 
colon cancer, clear cell carcinoma, thyroid cancer, lung cancer, squamous cell carcinoma, 
esophageal cancer, and Non-Hodgkin’s lymphoma. Of the 11 males seen for a family history 
suggestive of a BRCA mutation, 4 (9.09%) were noted to have a cancer diagnosis and 
included: adenocarcinoma of unknown primary, lymphoma, anal cancer, and duodenal 
cancer. The findings of other cancers, aside from breast cancer, diagnosed in our study 
cohort can be found in Table 4.  
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Table 4: Other Cancer Diagnoses by Indication  
Other Cancers Known 
Familial 
Mutation  
(n=54) 
Personal 
History 
(n=87)  
Family  
History  
(n=11) 
Overall 
(n=152)  
Prostate Cancer  5 (9.26%) 16 (18.39%) 0 21 (13.82%) 
Age of Diagnosis 
(Mean, SD) 
53.6 (4.56) 58.69 (6.43) 0 57.47 (6.33) 
Pancreatic Cancer  4 (7.41%) 35 (40.23%)  0 39 (25.66%) 
Age of Diagnosis 
(Mean, SD) 
45.33 (3.06) 57.09 (10.56) 0 56.16 (10.64) 
Other Cancers 10 (18.52%) 21 (24.14%) 4 (9.09%)  35 (23.03%) 
Age of Diagnosis 
(Mean, SD) 
57.00 (14.70) 62.61 (9.49) 59.25 (10.18) 58.60 (13.26) 
 
Several variables were looked at within our study to observe if there were particular 
trends or associations in regard to male breast cancer. These variables included 
gynecomastia, a history of a previous biopsy, radiation exposure, and if study participants 
chose to have a prophylactic mastectomy of their unaffected breast after receiving their 
breast cancer diagnosis.  Overall the numbers were very low for these miscellaneous 
findings and are summarized in Table 5. 
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Table 5: Miscellaneous Information for Study Cohort by Indication  
Miscellaneous 
Findings 
Known 
Familial 
Mutation  
(n=54) 
Personal  
History  
(n=87)  
Family  
History  
(n=11)  
Overall  
(n=152)  
Gynecomastia  1 (1.85%)  2 (2.30%) 0 3 (1.97%) 
Previous biopsy  0 2 (2.30%) 0 2 (1.32%) 
Radiation exposure  0 7 (8.05%) 1 (9.10%) 8 (5.26%) 
Prophylactic 
mastectomy  
0 2 (2.30%) 0 2 (1.32%) 
  
Table 6 summarizes the number of first and second degree relatives diagnosed with 
particular cancers per family of our study participants. Cancers included in this table are 
those known to be associated with BRCA mutations and included: breast cancer, male breast 
cancer, ovarian cancer, breast and ovarian cancer in the same individual, prostate and 
pancreatic cancer. Other cancers diagnosed in first and second degree relatives that are not 
known to be associated with BRCA mutations were collected from the electronic medical 
record and stored in our database; however, were not reported in this table.   The family 
history data is subdivided by the three indications males for seen for genetic counseling.  
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Table 6: Family History (First and Second Degree Relatives) Information Per Family  
Variable  Known Familial 
Mutation  
(n=54) 
Personal History 
(n=87)  
Family  
History  
(n=11) 
Family History  
(Per Family)  
Total number  
Mean (SD)  
Total number  
Mean (SD)  
Total number  
Mean (SD)  
Individuals with breast cancer              70  
2.55 (1.28) 
75 
0.86 (0.95) 
20 
1 (1.83)  
Individuals with male breast 
cancer 
2 
0.037 (0.19) 
0 2 
0.18 (0.40) 
Individuals with ovarian 
cancer  
28 
0.52 (0.72) 
10  
0.11 (0.35) 
1 
0.17 (0.30) 
Individuals with prostate 
cancer 
5 
0.09 (0.29)  
34 
0.39 (0.75) 
1 
0.17 (0.30) 
Individuals with pancreatic 
cancer  
8 
0.15 (0.45) 
7 
0.51 (0.31) 
5  
0.45 (1.2) 
Individuals with breast and 
ovarian cancer  
8  
0.15 (0.41) 
0  0 
 
Of the 152 males in our study, 84 had a height recorded at the time of their initial 
visit to MD Anderson (Figure 3). Therefore 68 males were missing a measurement for 
height from their patient history database. It is seen that the height is normally distributed. 
The mean for height in cm was 176.42 with a standard deviation of 6.54. The range of 
values recorded for height in cm was 164 to 191. The p-value obtained from the skewness 
test was 0.289. 
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Figure 3: Height (cm) of Study Participants  
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Of the 152 males in our study, 87 had a weight recorded at the time of their initial 
visit to MD Anderson (Figure 3). Therefore 65 males were missing a measurement for 
weight from their patient history database. It is seen that weight is not normally distributed 
within our cohort. By looking at the graph it is seen to be skewed to the left, as several males 
were noted to be overweight. The median for weight in kg was 87 with the IQR being from 
77 at the 25th percentile to 97 at the 75th percentile. The p-value obtained from the 
skewness test was <0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
n=84 
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Figure 4:Weight (kg) of Study Participants  
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Figure 4 shows the calculated body mass index, or BMI, of study participants 
calculated for the 84 males who had both a recorded height and weight. BMI measurement 
takes into account an individual’s height and weight and is calculated by the following 
formula: weight (kg) / [height (m)]2.  It is seen that BMI is not normally distributed within 
our cohort as it is skewed to the right. The median BMI is 27.75 with an IQR of 25.20 to 
30.98. The p value from the skewness test was 0.001.  
 
 
 
 
 
 
 
 
 31 
 
0
5
10
Fr
e
qu
en
cy
20 30 40 50
body mass index
Calculated BMI of All Study Participants
Figure 5: BMI for Males with Recorded Height and Weight 
 
 
 
 
 
 
 
 
 
 
BRCA Testing  
 Figure 6 displays the type of testing ordered across all three indications.  For each 
study participant it is important to understand that more than one test may have been 
ordered.  In total our cohort of 152 male, 174 BRCA tests were ordered.  The most 
commonly ordered tested was comprehensive testing, which accounted for 47% or 81 of the 
total 174 tests ordered.  It is seen that the least ordered test for our cohort was BART, as it 
accounted for only 8% of all of the tests ordered. 
 
 
 
 
 
 
 
 
 
n=84 
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Figure 6: Type of BRCA Testing Ordered  
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Figure 7 displays the overall BRCA test results of our cohort of 152 males. The 
majority of males were found to be negative 104 (68.42%).  In total 25 males (16.45%) were 
found to be BRCA2 positive and 22 males (14.47%)  were found to be BRCA1 positive, with 
one male (0.65%) being found to have both a BRCA1 and BRCA2 mutation.   
 
Figure 7: Overall BRCA Test Results  
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The BRCA test results subdivided by indication are shown in a graph in figure 8.  
The majority of individuals who were found to be BRCA1 positive (17) presented to clinic 
for a KFM, which accounted for 77.28% of all of the males who were BRCA1 positive. 
Similarly 17 males were found to be BRCA2+ who presented to clinic for a KFM, which 
accounted for 68% of all BRCA2+ males. The majority of males tested due to a personal 
history suggestive of a BRCA mutation (77) were found to be negative, which represented 
74.04% of all BRCA negative males. One study participant presented to clinic for a KFM 
and was found to have both a BRCA1 and BRCA2 which represented 0.65% of the total 
cohort. 
 
 
 
Figure 8: BRCA Test Results Stratified by Indication  
17 17 19
12
8
77
03 0
8
0
0
10
20
30
40
50
60
70
80
90
BRCA1+  BRCA2+ Negative Both BRCA1 &
BRCA2
BRCA Test Results by Indication 
Known Familial Mutation
Personal History
Family History
 
 
 
Table 7 summarizes both the type of BRCA testing ordered as well as the result of 
the testing ordered for each specific indication. For each study participant it is important to 
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understand that more than one test may have been ordered. The majority of study 
participants who were seen for a KFM had single site testing performed, (n=42, 77.78%). 
The second most commonly ordered test for males seen for this indication was the multisite 
panel (n=12), which would be ordered for anyone whose familial mutation was one of the 
three Ashkenazi Jewish founder mutations. The majority of individuals 74 (85.06%) seen for 
genetic counseling due to a personal cancer history suggestive of BRCA had comprehensive 
testing ordered. Similarly the majority of males, 6 (54.55%) who were seen due to a family 
history suggestive of a BRCA mutation had comprehensive testing performed.  
 
Table 7: BRCA Testing Ordered by Indication with Testing Results  
BRCA Testing Known Familial 
Mutation  
(n=54) 
Personal  
History  
(n=87)  
Family  
History  
(n=11) 
Single site (n) 
BRCA1+ 
BRCA2+ 
BRCA1+ & BRCA2+ 
Negative 
42 (77.78%) 
13 (30.95%)  
14 (33.33%)  
1 (1.85%) 
14 (33.33%) 
0 0 
Multisite/ 
Ashkenazi Panel (n)  
BRCA1 + 
BRCA2+  
Negative 
12 (22.22%) 
 
4 (33.33%) 
3 (25.00%) 
5 (41.67%) 
20 (22.99%) 
 
1 (%) 
1 (%) 
18 (%) 
5 (45.45%) 
 
1 (20.00%) 
0   
4 (66.67%) 
Comprehensive (n) 
BRCA1+  
BRCA2+ 
Negative  
2 (3.70%) 
0  
0 
2 (100%)  
73 (83.91%) 
1 (1.39%) 
7 (9.59%)  
65 (89.02%)  
6 (54.55%) 
2 (40.00%)  
0  
4 (60.00%) 
BART (n)  
BRCA1+  
BRCA2+ 
Negative  
1 (1.85%) 
0   
0   
1 (100%) 
11 (12.64%) 
0   
0   
11 (100%)  
2 (18.18%) 
0   
0   
2 (100%)  
 
  
Figure 9 displays the number of BRCA tests ordered per patient. The majority of our 
cohort, (86.84%, n=132) had one test ordered. A much smaller number, 18 males (11.84%), 
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had two tests ordered after receiving negative tests results from the first test ordered.  The 
most BRCA tests ordered for any one individual in our cohort was 3.  In the case that a male 
started with either single site or multisite testing then reflexed to comprehensive and then 
additionally reflexed to BART testing. There were only 2 males (1.32%) that had 3 BRCA 
tests ordered.  
 
 
Figure 9: Overall Number of BRCA Tests Ordered per Patient  
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BART testing has been clinically offered by Myriad as additional reflex testing for 
negative test results since August 2006. In our study cohort, 25 males were tested before 
BART testing was created which accounts of 16.45% of our total study cohort.  Out of these 
25 males, 9 had positive test results and 16 had negative test results.  Therefore 16 males 
were not offered BART testing as it did not yet exist.  Of the 127 males who were tested 
after August 2006, there were 39 males found to be positive and 79 were found to be 
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negative test results. Of the males who were negative, only 14 decided to proceed with 
BART testing and all 14 received negative test results. The results of males offered BART 
within our cohort as well as how many BART tests were ordered are summarized in figure 
10.  
 
Figure 10: Flowchart of BART Tests Offered and Ordered 
 
 
 
 
BRCAPro Scores  
Table 8 summarizes the median calculated BRCAPro scores by the three different 
indications. The median and IQR values are reported since the BRCAPro scores were found 
to be skewed with a p-value <0.00005.  The column denoted as “Overall” represents the 
entire cohort, not subdivided by indication, and has a median of 3.85 with an IQR from 0.3 
to 47.8. The indication with the highest median BRCAPro score of 49.4 was the known 
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familial mutation subgroup. The indication with the lowest median BRCAPro score of 0.6 
was a personal history of a BRCA associated cancer diagnosis. 
 
Table 8: BRCAPro Calculated Scores by Indication 
BRCAPro  
Score   
Known 
Familial 
Mutation  
(n=54) 
Personal  
History  
(n=87)  
Family  
History  
(n=11)  
Overall  
(n=152)  
Median  49.4 0.6 0.9  3.85 
IQR  39.5 - 50.0 0.1 - 3.9 0.4 - 9.1 0.3 - 47.8 
Range  0.2 - 100 0 - 88.6 0.2 - 32.6  0 - 100 
 
 
Table 9 summarizes the calculated BRCAPro scores for males diagnosed with breast 
cancer, pancreatic cancer, or prostate cancer who were seen due to their cancer diagnosis.  It 
is seen that the highest median BRCAPro score of 3.6 was obtained for males diagnosed 
with breast cancer. The IQR for these males was 0.7 – 12.3 and a range from as low as 0 to 
as high as 88.6. The lowest median BRCAPro score of 0.2 was obtained for males diagnosed 
with pancreatic cancer with an IQR of 0 – 0.3 and a range from as low as 0 to as high as 
20.2.  
 
 
Table 9: BRCAPro Calculated Scores by Cancer Diagnosis  
BRCAPro Number  Breast Cancer 
(n= 44) 
Pancreatic  
Cancer 
(n= 16)  
Prostate 
Cancer   
(n= 35) 
Median  3.6 0.2 0.45  
IQR  0.7 – 12.3  0 – 0.3 0.075 – 1.65  
Range   0 – 88.6  0 – 20.2  0 – 88.6 
 
 
 38 
 
ROC Curves  
The overall maximum Youden’s J of 0.165 was obtained at a BRCAPro threshold of 
32 at which sensitivity is equal to 75% and specificity is equal to 87%. Positive predictive 
value (PPV) at a threshold of 32 is equal to 72% and negative predictive value (NPV) at this 
threshold is equal to 88%. When the BRCAPro threshold is lowered to 12, sensitivity 
increases to 77%, specificity decreases to 75%, PPV decreases to 59% and NPV remains the 
same at 88%. The value for specificity and PPV decrease when the BRCAPro score is 
lowered due to the fact that the number of false positives increases. This calculation 
included the entire cohort of 152 individuals and is represented in figure 11.   
 
Figure 11: Overall ROC Curve Including All Study Participants  
0.
00
0.
25
0.
50
0.
75
1.
00
Se
n
si
tiv
ity
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.8070
Overall ROC Curve Including All Study Participants 
 
 
 
For males with a KFM a maximum Youden’s J of 0.369 was obtained at a BRCAPro 
threshold of 32 at which sensitivity is equal to 94% and specificity is equal to 42%.  PPV at 
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a threshold of 32 is equal to 75% and NPV at this threshold is equal to 80%. The ROC curve 
for males seen for a KFM is seen in figure 12.  
 
 
Figure 12: ROC Curve for Males with a Known Familial Mutation undergoing 
Predictive BRCA Testing   
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For males with a personal history suggestive of a BRCA mutation the area under the 
ROC curve (AUC) was calculated as .50. Therefore the discriminatory value of the 
BRCAPro model for males with an indication of personal history suggestive of a BRCA 
mutation, or males seen with a personal diagnosis of either breast, prostate, or pancreatic 
cancer is no different than random chance.  The ROC curve for males with this indication is 
found in figure 13. 
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Figure 13: ROC Curve for Males with a Personal History of a BRCA Associated 
Cancer  
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For males with a family history suggestive of a BRCA mutation a maximum 
Youden’s J of 0.542 was obtained at a BRCAPro threshold of 2 at which sensitivity is equal 
to 67% and specificity is equal to 88%. PPV at a threshold of 2 is equal to 67% and NPV at 
this threshold is equal to 88%. This indication subgroup had a very small n, as only 11 males 
for seen for this indication. The ROC curve constructed for this sub section of our cohort is 
found in figure 14.  
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Figure 14: ROC Curve for Males with a Family History Suggestive of a BRCA 
Mutation  
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For males diagnosed with breast cancer it was found that a BRCAPro threshold of 
56.2 predicts the presence of a BRCA mutation perfectly, since the only two individuals who 
tested positive were the only men with breast cancer and an indication of 2 who had a score 
higher than 56.2.  The ROC curve for males diagnosed with breast cancer is found in figure 
15. 
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Figure 15: ROC Curve for Males Diagnosed with Breast Cancer  
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For males who were diagnosed with prostate cancer, a maximum Youden’s J of 0.44 
was obtained at a BRCAPro threshold of 1.0 at which sensitivity is equal to 67% and 
specificity is equal to 77%. PPV at a threshold of 1.0 is equal to 40% and NPV at this 
threshold is equal to 91%. The ROC curve for males diagnosed with prostate cancer is seen 
in figure 16.  
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Figure 16: ROC Curve for Males Diagnosed with Prostate Cancer 
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For males with pancreatic cancer a maximum Youden’s J of 0.46 was obtained at a 
BRCAPro threshold of 0.3. The ROC curve for pancreatic cancer patients demonstrates that 
the BRCAPro5.1 model does not seem to be predictive for this particular patient population 
in identifying BRCA mutation carriers.  The AUC calculated was 0.56 which demonstrates a 
discriminating ability that is not much different than random chance. The ROC curve for 
males diagnosed with pancreatic cancer is found in figure 17.  
 
 
 
 
 
 
 
 
 
 
 
 44 
 
Figure 17: ROC Curve for Males Diagnosed with Pancreatic Cancer  
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A ranksum statistical test was run on the two variables of breast cancer development 
and BMI. There was an association found due to a p value that was <0.00005. The median 
BMI for males without breast cancer was 26.02 with an IQR of 24.57 to 28.40. The median 
BMI for males diagnosed with breast cancer was 30.78 with an IQR of 27.42 to 33.43.  The 
box and whisker plot of this association is shown in figure 18.  
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Figure 18: Box and Whisker Plot of Breast Cancer Development by BMI 
 
 
 
An association was found between development of pancreatic cancer and BMI, as a 
p-value of 0.0002 was obtained by running a ranksum test. The median BMI for males not 
diagnosed with pancreatic cancer was 29.21 with an IQR of 26.04 to 32.08.  The median 
BMI for males diagnosed with pancreatic cancer was 25.95 with an IQR of 23.95 to 27.73. 
The box and whisker plot of this association is shown in figure 21.  
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Figure 19: Box and Whisker Plot of Pancreatic Cancer Development by BMI  
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DISCUSSION 
This is the first study that seeks to evaluate the accuracy of the BRCAPro5.1 risk 
assessment model specifically in males.  The aim of our study was to see how this particular 
model performed overall in our cohort of males seen for numerous different clinical 
indications for BRCA genetic testing. Additionally, other factors such as ethnicity, age of 
diagnosis, presence of gynecomstatia, weight, height, etc., were obtained from the medial 
records of our study population and also tested for significance.  
 
BMI  
Males who had a higher BMI had a statistically significant increased risk of breast 
cancer (p<0.00005). According to the World Health Organization, BMI calculations can be 
classified into four categories: underweight with a BMI <18.5, normal with a BMI between 
18.5 to 24.9, overweight with a BMI of 25.0 to 29.9 and obese with a BMI over 30 [44].  
Previous studies have shown that having a BMI ≥ 25.0 confers an increased risk for cancers 
specifically: endometrial cancer in women, postmenopausal breast cancer in women, renal 
cell carcinoma, colon cancer particularly in males and esophageal adenocarcinoma [45].   
This finding is consistent with the current literature on increased BMI seen in males with 
breast cancer. One study published in 2002 reported a trend seen in 43 male breast cancer 
patients towards having a higher BMI, as the average BMI was reported to be 26.54 [46].  
At this point in time the mechanisms for increased BMI in relation to male breast cancer are 
not fully understood however, it is hypothesized that having an increased surface area of 
breast tissue may predispose to the development of breast cancer in males. Another 
hypothesis is that obesity lowers IGFBP 1 & 2 and thus increases the availability of IGF-1.  
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Increased bioavailability of IGF-1 along with insulin have been thought to increase cell 
proliferation and decrease apoptosis, although this association has yet to be proven [47].  
There is some debate as to which measure is most appropriate in order to investigate 
associations between weight and cancer development, as some feel other measures such 
waist-to-hip ratio (WHR) measurement may be more appropriate in order to access for body 
fat distribution which is not accounted for with BMI. Other limitations previously noted 
with BMI calculations is the fact that it performs with less accuracy in individuals >65 years 
old as well as in Asian individuals [44]. BMI was chosen as the most appropriate calculation 
for our study cohort, due to the fact that recorded heights and weights were able to be found 
within the electronic medical record, other measurements such as WHR were not recorded. 
Also very few males were noted to be of Asian ancestry within our study cohort.  
In our cohort of males who developed pancreatic cancer, it was noted that their 
median BMI was actually lower in comparison to males who did not develop pancreatic 
cancer. The median BMI for males diagnosed with pancreatic cancer was 25.95 with an IQR 
of 23.95 to 27.73. The median BMI for males without pancreatic cancer was 29.21 with an 
IQR of 26.04 to 32.08.  Previous studies have shown that there is an association between 
increased BMI to have an increased risk for pancreatic cancer in both males and females 
[45]. However, our cohort does not shown this same association, which may be explained by 
several different factors. The height and weight measurements used to calculate BMI were 
taken from the patient’s initial clinic visit, since a symptom of pancreatic cancer can be 
severe weight loss it can be postulated that patients with pancreatic cancer may have been 
under their typical weight at the time of their initial visit. Additionally, it was not noted 
whether patients in our cohort had a history of cigarette or tobacco use, which have been 
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found to be associated with the development of pancreatic cancer. Males who had a positive 
history of tobacco use may have lower recorded weights due to the increase in metabolism 
seen with tobacco use. Additionally as seen with male breast cancer and pancreatic cancer, 
some studies suggest that being overweight or obese as defined by one’s BMI calculation is 
a risk factor in the development of prostate cancer. In our study cohort no significant 
difference was observed between the median BMI of males with prostate cancer compared 
to the median BMI of males without prostate cancer.  
 
BRCA Mutation Results  
 In our study cohort it was observed that more males were found to be BRCA2 
positive (25) than BRCA1 (23) positive. There does not appear to be a significant difference 
between these two groups. The same number of BRCA1 and BRCA2 mutations, 17, were 
identified for males in our cohort who underwent testing for a KFM. Perhaps the finding of 
slightly more BRCA2 mutation carriers can be attributed to the high number of males seen 
within our cohort who were diagnosed with pancreatic cancer, as it is characterized in the 
literature that BRCA2 mutation carriers confer a higher lifetime risk for pancreatic cancer in 
comparison to BRCA1 carriers [5]. Overall in our cohort, 8 males were found to have 
pancreatic cancer and a BRCA2 mutation while 1 male was found to have pancreatic cancer 
and a BRCA1 mutation, therefore when we take these males diagnosed with pancreatic 
cancer out, 21 males were found to be BRCA1 mutation carriers and 17 males were found to 
be BRCA2 mutation carriers.  
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BRCAPro5.1 Calculations  
When looking at the median BRCAPro score calculated by indication, there was a 
large difference in the median generated for males with a KFM in comparison to males with 
an indication of either having a personal history of a BRCA related cancer diagnosis or for a 
suggestive family history. For males with a KFM, the median BRCAPro score was 49.4, 
which is expected as individuals undergoing predictive testing are commonly at a 50% risk 
to have inherited the particular familial mutation based purely on autosomal dominant 
inheritance and pedigree analysis.  The BRCAPro risk assessment model can alter an 
individual’s likelihood to test positive based on age of the individual at the time of testing 
and personal history of cancer diagnoses. An example from our cohort that illustrates the 
adjustment to a BRCAPro calculation based on age for males undergoing predictive testing 
is seen with an unaffected male who underwent predictive testing at the age of 58 with a 
BRCAPro score of 47.4 as compared to an unaffected male who had predictive testing at the 
age of 20 who was found to have a BRCAPro score of 50%, both individuals tested positive 
for their known familial mutations, which were both BRCA1 mutations.   
When looking at the median BRCAPro scores for males with either a personal 
history suggestive of a BRCA mutation or with an indication of a family history suggestive 
of a BRCA mutation, they appear low with the median scores being 0.6 and 0.9, respectively. 
The low scores may be explained by the fact that the only cancers calculated in the current 
BRCAPro5.1 model are breast and ovarian cancers. Therefore, males who are themselves 
diagnosed or who have family members who are diagnosed with other BRCA associated 
cancers such as prostate or pancreatic cancers are counted as an unaffected individual by the 
model. Although it is known that BRCA mutation carriers are at increased lifetime risks to 
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develop both prostate cancer in males and pancreatic cancer, it may prove to be difficult in 
assessing how these cancers best fit into the mathematical equation utilized in the BRCAPro 
model.   
A statistically significance difference was noted in regard to the calculated BRCAPro 
scores across the three indications with a p-value of 0.0001. However no significant 
difference was noted in regard to ethnicity or the presence of Ashkenazi Jewish ancestry in 
regard to BRCAPro scores, which may be due to the small number of individuals in these 
categories. Within our cohort it was found that age of diagnosis was not statically significant 
(p = 0.68).   
 
Overall Performance of the BRCAPro5.1 Model  
 When looking at the overall ROC curve constructed for the entire cohort the model 
performed quite well at an AUC of 0.8070 since an AUC of 1.00 is representative of a 
“perfect test” or one with a perfect discriminating ability in determining BRCA carriers from 
non-carriers.  At a BRCAPro threshold of 32, obtained through calculating the maximum 
Youden’s J value, sensitivity of the BRCAPro model was equal to 75% and specificity was 
equal to 87%. The positive predictive value at the threshold of 32 was 72% while the 
negative predictive value was 88%.  From these calculations it can be deduced that at our set 
threshold, BRCAPro had a better ability to determine males who were negative for BRCA 
mutations than positive.   
The BRCAPro model can be used as not only a guide on how likely it is for a given 
individual to be a BRCA mutation carrier, but also under certain circumstances may in fact 
serve as a substitute for testing [41]. Thus when deciding at what level to set our threshold 
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for BRCAPro scores to calculate our ROC curves, it was decided to determine the optimal 
threshold by utilizing the maximum Youden’s J calculation, since equal importance was 
placed on sensitivity and specificity. In the case of substituting BRCAPro scores for actual 
BRCA testing it can be argued that harm may be inflicted by calling either false negatives or 
false positives. It is a matter of opinion as to which of these outcomes is worse. Calling false 
negatives inaccurately assures individuals that they are not at an increased risk to develop 
BRCA associated cancers. If these individuals are not actively being screened for their 
increased cancer risks then there is potential for the development and advancement of  
cancers. The psychosocial impacts of calling false negatives must also be factored in when 
discussing potential harm caused to these individuals. On the converse side, calling false 
positives may also create certain unwarranted psychosocial harm.  Additionally, false 
positives may inflict harm by means of an increased proportion of health care dollars being 
spent to ensure increased screening for these individuals who in actuality are not at 
increased risk.   
 
ROC Curves Subdivided by Indication  
 The ROC curve constructed for males seen with a KFM had it’s maximum Youden’s 
J at a BRCAPro threshold of 32, at which sensitivity is equal to 94% and specificity is equal 
to 42%. The AUC was calculated to be 0.68, which corresponds to a relatively poor 
discriminating ability, similarly the AUC calculated for males with a personal history 
suggestive of a BRCA mutation was found to be 0.50, which is the same discriminating 
ability as random chance. This finding may be explained by the fact that neither prostate or 
pancreatic cancers can be accounted for in the BRCAPro model, which could thus 
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significantly lower the BRCAPro calculations for males with personal histories of these 
cancers and/or family histories of these particular cancers.  
 The least common indication to seek genetic counseling in our cohort was that of 
having a family history suggestive of a BRCA mutation, as only 11 males were seen for this 
indication. The AUC calculated by the ROC curve was 0.77, and therefore there was a 
decent discriminating ability with the BRCAPro model for males with this indication. Thus, 
BRCAPro may be helpful for men with family histories of breast and/or ovarian cancer 
while not helpful for men with family histories abundant in prostate or pancreatic cancer 
diagnoses.  
 
ROC Curves Subdivided by Cancer Development and Type 
There were seven male probands included in the initial study that validated the use of 
the BRCAPro model in the clinical setting only three of which had male breast cancer [41]. 
All three were found to be BRCA2 mutation carriers which may have skewed the results 
with the BRCAPro scores calculated for these three males all being found to be greater than 
95. Which is similar to our finding that BRCAPro had a perfect discriminating ability in 
males with breast cancer at a BRCAPro calculation above 56.2 [41].   
One previously published paper aimed to evaluate the use of the BRCAPro5.0 model 
in 102 Italian male breast cancer patients, and found at a set threshold of 10% the model had 
a sensitivity of 0.80, specificity of 0.78, positive predictive value of 0.29 and a negative 
predictive value of 0.97 [34]. This particular study utilized this threshold as this is the 
threshold value that the FHAT model uses [34]. Our study threshold used for our male 
breast cancer patients was obtained by calculating the Youden’s J value.  However when we 
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set our BRCAPro threshold to 10% we obtained a sensitivity of 100%, specificity of 76%, 
positive predictive value of 16% and negative predictive value of 100%. Therefore our 
findings were quite similar to those produced by the previous study conducted by Zanna et 
al, as both studies found the BRCAPro model to have higher sensitivity than specificity and 
very high negative predictive values with low positive predictive values. 
The ROC curve constructed for males who were diagnosed with prostate cancer gave 
a calculated AUC of 0.69. The ROC curve constructed for males with pancreatic cancer seen 
for genetic counseling due to their personal cancer diagnosis had a AUC of 0.56. Again this 
finding may be due to the fact that males with a prostate cancer diagnosis are treated as 
unaffected individuals. In many cases prostate cancer may be a sporadic cancer due to 
advancing age, however early onset prostate cancer may in fact be more suggestive of a 
BRCA mutation. However, the current BRCAPro model has no way to account for such 
differences.  
 
Study Limitations  
 This research project was a retrospective chart review, and there are several 
limitations noted.  First and foremost, the overall study size is rather small with a total 
cohort of 152 males. Additionally all males in this study were patients at the same hospital 
and therefore the results may not translate to all other male patient populations seeking 
BRCA testing since demographic information may be different at different cancer centers.  
 Due to the nature of a retrospective chart review, some information was missing 
from the medical records for our study participants. For instance, height and weight of study 
participants were ascertained from the patient history database which is information taken 
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during their first clinical visit by a nurse.  Many study participants were missing this 
information as 77 males were missing a recorded height and 74 males were missing a 
recorded weight.  Other variables such as gynecomastia were researched in this study; 
however, it was only noted as being present if documented in the medical record. Therefore, 
there could have been more male patients with gynecomastia who were not denoted to have 
this condition if it was left out of their dictated medical notes.  
 An additional limitation of our study is the fact that family history is patient reported, 
which could potentially lead to misrepresentation of the family history as cancer diagnoses 
may be underestimated, overestimated, and/or simply incorrect. Study participants with a 
personal diagnosis of cancer were able to be verified through pathology reports from MD 
Anderson, although patients that present for a second opinion to MD Anderson may have 
pathology reports from an outside hospital or no pathology report present in their medical 
record.   
 One last limitation of this study can be attributed to the way clinical BRCA testing is 
currently conducted in the United States through Myriad Genetics Laboratories.  The most 
comprehensive of testing to date includes both comprehensive sequencing as well as 
reflexing when a negative comprehensive test result is received to a large arrangement test 
that uses MLPA analysis known as BART®.  In our study cohort only 14 (9.21%) males 
underwent BART® testing. Therefore the majority of our cohort did not receive the absolute 
most comprehensive testing available as of 2012. There are numerous reasons a study 
participant may not have BART® performed, whether it was that they were tested before 
August 2006 when the test first became clinically available or they did not wish to incur the 
additiona cost of the test.  For study participants who tested negative through either single 
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site analysis or multisite analysis, they would then need to reflex to comprehensive 
sequencing and then additionally BART® testing in the event the comprehensive 
sequencing was negative to be considered to have the most comprehensive testing to date. 
However, the residual risk to have a BRCA mutation after having either negative single site 
or negative multisite testing is very small and therefore many patients do not wish to 
continue further BRCA testing, especially with the relatively high cost of testing.  
 
Implications and Future Research  
 Currently figures quoted in the medical literature provides a wide range of the 
likelihood a case of male breast cancer is attributable to a BRCA mutation from 4% to 40%. 
Although the overall sample size of males who had breast cancer without having a KFM is 
rather small in our cohort at 46, only 2 of these males had a BRCA mutation more 
specifically a BRCA2 mutation, which is a significantly lower number than expected.  
Clearly more research and attention needs to be placed on determining what factors are 
causing male breast cancer, as the literature appears to overestimate the contribution that 
BRCA mutations have in regard to male breast cancer. There may in fact be specific genetic 
factors aside from BRCA mutations that play a role in the development of male breast 
cancer; therefore, research is needed to identify what these genetic factors are.  
 
Conclusion 
 In conclusion, our study was able to find the ideal BRCAPro score threshold for both 
clinical indications and cancer subtype within our cohort. When lowering the BRCAPro 
score closer to the study populations overall median BRCAPro score (3.85) it was 
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demonstrated that the model performs inadequately. For males with an indication of having 
a personal cancer history, BRCAPro5.1 performed the same as random chance. Our study 
discovered that the BRCAPro5.1 model had perfect discriminating ability for males with 
breast cancer at a threshold of 56.2, as all of our male breast cancer patients with a BRCA 
mutation had a BRCAPro score well above this threshold. However, it is important to note 
that our sample size of male breast cancer patients was small, and this finding should not be 
applied to other male breast cancer cohorts. Additionally, adjusting the threshold to 10 
demonstrates that BRCAPro is overestimating the likelihood that a man with breast cancer 
would test positive. The discriminating ability of the model for males with a personal or 
family history of pancreatic or prostate cancer was very poor. Directions for the future 
should include a large multicenter study combining patients diagnosed with male breast 
cancer to increase the overall sample size and further evaluate the validity of the findings 
from our study.  Lastly, consideration should be given to determine a way to account for 
prostate and pancreatic cancers in future versions of the BRCAPro risk assessment model, 
which in turn might better evaluate the risk for males to test positive for BRCA mutations.   
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